Sánchez-Cano FM, Sánchez-Rico Y

Language: Spanish
References: 11
Page: 439-442
PDF size: 203.90 Kb.

ABSTRACT

Background: The antiphospholipid syndrome is an autoimmune disease in which its thrombotic and obstetric manifestations prevail. However, in the recent years the non-criteria manifestations of the disease have gained strength. One of these is the nephropathy associated to antiphospholipid syndrome, which traditionally is divided into acute and chronic lesions; the first is displayed by the thrombotic microangiopathy and more frequently recognized in the context of the catastrophic antiphospholipid syndrome, while the chronic lesions are frequently displayed by occlusive vasculopathy and fibrous hyperplasia of the intima of small renal vessels.
Clinical case: A 31-year-old female patient with a recent diagnosis of systemic lupus erythematosus, it was additionally suspected lupus nephritis and the associated antiphospholipid syndrome. The renal biopsy of the patient showed nephropathy associated to antiphospholipid syndrome.
Conclusions: Antiphospholipid syndrome has traditionally been diagnosed for its thrombotic and obstetric complications; however, there are manifestations that must be taken into account at the time of suspicion or diagnostic confirmation, among which is the nephropathy associated with this disease.

REFERENCES

1. Schreiber K, Sciascia S, De Groot PG, Devreese K, Jacobsen S, Ruiz-Irastroza G, et al. Antiphospholipid syndrome. Nat Rev Dis Prim 2018;4. doi: 10.1038/nrdp.2017.103.

2. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378(21):2010- 21. DOI: 10.1056/NEJMra1705454.

3. Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14(5):401-14. doi: 10.1016/j.autrev.2015.01.002.

4. Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. Nat Rev Rheumatol 2017;13(9):548-60. doi: 10.1038/nrrheum.2017.124.

5. Bienaimé F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int 2017;91(1):34-44. doi: 10.1016/j.kint.2016.06.026.

6. De Azevedo FVA, Maia DG, De Carvalho JF, et al. Renal involvement in antiphospholipid syndrome. Rheumatol Int 2018;38:1777. DOI: 10.1007/s00296-018-4040-2.

7. Nasri H. Antiphospholipid syndrome-associated nephropathy: Current Concepts 2013;2(1):1-2.

8. Daugas E, Nochy D, Le DU, Huong THI, Duhaut P, Beaufils NE, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002;42-52.

9. Associations C, Outcome L, Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies. Arthritis Rheum 2004;50(8):2569-79. doi: 10.1002/art.20433.

10. Sant F, Espinosa G, Cervera R, Arrizabalaga P. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 2011;20:721- 729. doi: 10.1177/0961203310397410.

11. Bataillon G, Seilhean D, Noël L, Ph D, Snanoudj R, Ph D, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;3714371(24)pp:303-12. doi: 10.1056/NEJMoa1312890.